IVCC receives $50 million to develop new insecticides

NewsGuard 100/100 Score

The Innovative Vector Control Consortium (IVCC) has received $50 million from the Bill & Melinda Gates Foundation to continue its work to develop new insecticides for the improved control of mosquitoes and other insects which transmit malaria, dengue and other neglected tropical diseases.

IVCC was established in 2005 with an initial grant of $50.7 million over five years from the foundation. Since then, an unprecedented development pipeline of new, reformulated and repurposed insecticides has been established in partnership projects with leading global chemical companies. A suite of information systems and diagnostic tools for the more effective and efficient use of insecticides has also been developed, with these products now nearing the end of their development phase and being readied for rollout in the coming year.

The new five year grant will support new and ongoing projects to develop new Active Ingredients for insecticides and to complete the existing portfolio of insecticide formulation and repurposing projects.

Chief Executive Officer Professor Janet Hemingway explained: "The need for new insecticides has never been greater. Increased funding for control programmes is saving thousands of lives but malaria is still killing one child in Africa every 45 seconds. Resistance to insecticides is increasing at an alarming rate and we must find new alternatives even if we are to stay still in our battle against this and other vector borne diseases.

"This award allows us continue the pioneering work we're doing in partnership with the chemical industry to find and develop totally new classes of insecticide to help put an end to this needless loss of life. Our strategic aim is to provide three new Active Ingredients for use in public health insecticides by 2020."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Innovative approaches needed to overcome health system barriers in malaria vaccination